DiaSorin Inc. has received FDA clearance for their LIAISON Direct Renin immunoassay to aid in the diagnosis and treatment of certain types of hypertension.
"Hypertension affects approximately 67 million US adults and is the major contributor to cardiovascular diseases worldwide. We are proud to introduce the first, fully automated, chemiluminescent Direct Renin test to assist in differentiation of this disease. With such a capability now available to clinical laboratories, DiaSorin's LIAISON Direct Renin assay will better enable clinicians to treat and manage this disease", said John Eskdale, president, DiaSorin Inc.
DiaSorin has over 20 years experience in Renin in vitro diagnostic testing.